Disease · MONDO_0009891
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PEGASYS vs Hydroxyurea: Number of Participants With Major Cardiovascular Events After Therapy | 1 of 82 | 1 of 86 | 168 | NCT01259856 | Trial comparisons |
| PEGASYS vs Hydroxyurea: deaths from any cause | 0 of 82 | 1 of 86 | 168 | NCT01259856 | Trial comparisons |
| PEGASYS vs Hydroxyurea: serious adverse events | 14 of 82 | 4 of 86 | 168 | NCT01259856 | Trial comparisons |
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28 | 7 of 74 | 0 of 75 | 149 | NCT02038036 | Trial comparisons |
| Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Achieving a Complete Hematological Remission at Week 28 | 17 of 74 | 4 of 75 | 149 | NCT02038036 | Trial comparisons |
| Ruxolitinib vs Best Available Therapy (BAT): Number of Participants With Transformation Free Survival Events | 4 of 74 | 3 of 75 | 149 | NCT02038036 | Trial comparisons |
| Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Developing Thrombosis | 0 of 74 | 0 of 75 | 149 | NCT02038036 | Trial comparisons |
| Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Achieving Hematocrit (Hct) Control at Week 28 | 46 of 74 | 14 of 75 | 149 | NCT02038036 | Trial comparisons |
| Ruxolitinib vs Best Available Therapy (BAT): Number of Participants With Overall Survival (OS) Events | 3 of 74 | 6 of 75 | 149 | NCT02038036 | Trial comparisons |
| Ruxolitinib vs Hydroxyurea: serious adverse events | 5 of 54 | 4 of 56 | 110 | NCT01632904 | Trial comparisons |
| GIVINOSTAT + MTD Hydroxyurea_1 vs GIVINOSTAT + MTD Hydroxyurea_2: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT00928707 | Trial comparisons |
| GIVINOSTAT + MTD Hydroxyurea_1 vs GIVINOSTAT + MTD Hydroxyurea_2: serious adverse events | 2 of 22 | 1 of 22 | 44 | NCT00928707 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009891/comparisons